Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics Limited, a clinical-stage biotech firm specializing in psilocin-based treatments, announced that CEO Jason Carroll will present at the TechKnow Invest Roadshow in Sydney and Melbourne, with livestreams available for remote investors. The company’s lead program, TRP-8803, has shown promise in a Phase 2a trial for binge eating disorder, and they are currently conducting trials for fibromyalgia and irritable bowel syndrome. TRP-8803 aims to improve the efficacy and patient experience over oral psilocybin treatments.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.